Cardiorespiratory fitness and response to exercise treatment in depression
Md Shafiqur Rahman, Björg Helgadóttir, Mats Hallgren, Yvonne Forsell, Brendon Stubbs, Davy Vancampfort and Örjan Ekblom

Background
Exercise improves cardiorespiratory fitness (CRF) and reduces depressive symptoms in people with depression. It is unclear if changes in CRF are a predictor of the antidepressant effect of exercise in people with depression.

Aims
To investigate whether an increase in CRF is a predictor of depression severity reduction after 12 weeks of exercise (trial registration: DRKS study ID, DRKS00008745).

Method
The present study includes participants who took part in vigorous (n = 33), moderate (n = 38) and light (n = 39) intensity exercise and had CRF information (as predicted maximal oxygen uptake, \( V̇O_{2max} \)) collected before and after the intervention. Depression severity was measured with the Montgomery–Åsberg Depression Rating Scale (MADRS). \( V̇O_{2max} \) (L/min) was assessed with the Åstrand-Rhyming submaximal cycle ergometry test. The main analysis was conducted pooling all exercise intensity groups together.

Results
All exercise intensities improved \( V̇O_{2max} \) in people with depression. Regardless of frequency and intensity of exercise, an increase in post-treatment \( V̇O_{2max} \) was significantly associated with reduced depression severity at follow-up (\( B = −3.52, 95\% CI −6.08 to −0.96; \)) adjusting for intensity of exercise, age and body mass index made the association stronger (\( B = −3.89, 95\% CI −6.53 to −1.26; \)). Similarly, increased \( V̇O_{2max} \) was associated with higher odds (odds ratio = 3.73, 95% CI 1.22–11.43) of exercise treatment response (≥50% reduction in MADRS score) at follow-up.

Conclusions
Our data suggest that improvements in \( V̇O_{2max} \) predict a greater reduction in depression severity among individuals who were clinically depressed. This finding indicates that improvements in \( V̇O_{2max} \) may be a marker for the underpinning biological pathways for the antidepressant effect of exercise.

Declaration of interest
None.

Keywords
Depression; cardiorespiratory fitness; exercise.

Physical exercise is recommended for the treatment of mild-to-moderate depression, both as monotherapy and as an adjunct to conventional treatment.1–4 Currently, there is a strong focus in the literature on the role of cardiorespiratory fitness (CRF) in exercise treatment studies of depression.5,6 It is well established that physical exercise levels, especially vigorous intensity activities, influence CRF.1,7 A recent systematic review of three prospective cohort studies (n = 1 142 699) concluded that lower CRF increases the risk of subsequent depression among non-depressed people at baseline.6 It has also been shown that individuals who maintain their CRF across the lifespan have a reduced risk of a depressive episode.8 These findings suggest CRF (or the maximal oxygen uptake, \( V̇O_{2max} \)) is inversely associated with risk for depression. Papasavvas et al9 suggest that an inverse association between \( V̇O_{2max} \) and depression severity at follow-up after controlling for potential moderators would imply the presence of endogenous processes between \( V̇O_{2max} \) and treatment response in depression. At present, CRF or \( V̇O_{2max} \) is not routinely considered when determining treatment approaches for depression, as the role of CRF or \( V̇O_{2max} \) in relation to depression risk and recovery is still not fully understood. However, to optimise treatment efficacy, it is important to identify predictors of treatment response. The present study investigated if an increase in CRF (expressed as \( V̇O_{2max} \)) leads to a reduction in depression severity or predicts a better treatment response after 12 weeks of physical exercise treatment.

Data is derived from a single-blind, parallel randomised control trial, Regassa, comparing the effectiveness of physical exercise, internet-based cognitive–behavioural therapy and treatment as usual for mild-to-moderate depression. Primary findings of Regassa are available elsewhere.10,11 Primary care patients from six county councils in Sweden (Stockholm, Skåne, Västra Götaland, Kronoberg, Blekinge and Västmanland) aged ≥18 years and scoring ≥9 on the Patient Health Questionnaire (PHQ-9)12 were included. Recruitment began in February 2011 and the last participants ended their treatment in March 2013. Those presenting with severe somatic disorders, primary drug or alcohol use disorder and psychiatric disorders requiring specialist treatment were excluded. Following an initial consultation with their primary healthcare provider, suitable patients were referred to a research nurse who administered the baseline questionnaires and confirmed eligibility by conducting a thorough patient interview that included a psychiatric diagnostic assessment using standardised tools (described below). Before the study began, the research nurses were trained by a psychiatrist to interview patients and administer the questionnaires in a consistent manner. After obtaining informed consent, patients (n = 945) were randomised to one of the three treatment conditions by an independent clinical research organisation; the Karolinska Trial Alliance, where individual patients were
treated as the ‘unit’ of randomisation. The blocks were unknown to the researchers, and a computer generated the group allocation. This procedure ensured that researchers responsible for the baseline and post-treatment assessments were masked to the patient’s group allocation. The present study includes participants from the physical exercise arm (n = 316) using a prospective design. Given the availability of $\dot{V}O_{2\text{max}}$ information at baseline and follow-up, the analytical sample of this study consisted of 110 participants. The ethical review board at the Karolinska Institutet, Sweden, approved the study (Dnr 2010/1779-31/4) and the trial is registered with the German Clinical Trial Register (DRKS study ID: DRKS00008745). The study was carried out in accordance with the latest version of the Declaration of Helsinki.

Physical exercise

Participants in the physical exercise arm were randomised to one of three supervised exercise conditions: (a) light exercise consisting of yoga-based stretching and balance exercise classes; (b) moderate exercise consisting of intermediate level group aerobic classes, and (c) vigorous exercise that included more strenuous aerobic exercises/bodyweight strength training classes. To ensure the intensity levels differed between the recommended classes, members of the research team designed classes of differing intensity that were tested using indirect calorimetry and pulse watches in a laboratory setting. They then attended different classes at the gym using pulse watches and compared the results with the laboratory classes. The results were used to select classes of differing intensities to recommend to the participants (as described above). Additionally, measurements of heart rate from the sessions were then compared with various classes at the gym, also to identify classes of similar intensity. Participants were asked to join supervised pre-existing group classes (corresponding to their assigned intensity level) lasting 55 min, three times per week for 12 weeks. A free 12-week membership card was provided to all participants. Phone calls and text messages were sent if participants did not attend the pre-arranged weekly meetings with their assigned trainer. On average participants of the present study attended about 14.43 sessions. The frequency of training and drop-out rate between the intensity groups did not differ. Previous findings from the Regassa study found no large differences between intensity types in reducing depression following 12 weeks of intervention.13

CRF

CRF was assessed as $\dot{V}O_{2\text{max}}$ (L/min) and predicted from the Åstrand–Rhyming submaximal cycle ergometry test,14,15 which is validated16,17 and relies on the assumption of a linear relationship between heart rate and $\dot{V}O_{2}$ in higher pulse intervals. The Åstrand–Rhyming test consisted of a 6 min exercise bout on a mechanically broken cycle ergometer (Monark 828E, Monark Exercice, Vansbro, Sweden). The participant cycled at a pedalling frequency of 50 rpm and rate of work was set to elicit a heart rate between 120 and 150 beats per minute. Prior to testing, participants were asked to refrain from caffeine, nicotine, alcohol, heavy meals and intense exercise for a specified period of time. Heart rate during exercise was measured using telemetry (Polar Electro Oy, Tempere, Finland). $\dot{V}O_{2\text{max}}$ (L/min) values were adjusted for age according to the Åstrand testing protocol.14 All participants from the different exercise arms were invited to undertake the aerobic fitness test. A total of 181 participants at baseline (125 at follow-up) provided valid $\dot{V}O_{2\text{max}}$ test results. Of these, $\dot{V}O_{2\text{max}}$ (L/min) information at baseline and follow-up was available for 112 individuals. There are numerous reasons (for example the patient had influenza, feeling dizzy, tiredness or fatigue) why valid $\dot{V}O_{2\text{max}}$ (L/min) test results could not be determined for many participants. Two participants using beta-blockers were excluded from the analysis (the study flow chart can be found in supplementary Fig. 1 available at https://doi.org/10.1192/bjo.2018.45). Work rate distribution before and after treatment at high- and low-intensity level was between 50 to 150 Watts.

Depression assessment

Depression at baseline (before randomisation) and after 12 weeks of physical exercise was measured by the Montgomery–Åsberg Depression Rating Scale (MADRS – Clinician Rated), which is sensitive to change over time.18 The total MADRS score ranges from 0 to 60 and higher scores indicate more severe depression. In order to assess the treatment’s effects in terms of clinically significant changes in depression severity, a binary outcome variable was also analysed, in addition to the continuous score. This binary variable was categorised as a 50% or greater reduction in MADRS scores at follow-up compared with baseline (treatment responders) versus lower or no reduction (treatment non-responders).

Covariates

Covariates used in this study are primarily self-reported and include: age, gender, body mass index (BMI), education, ethnicity, antidepressants (binary: yes or no) and tobacco use at baseline, and habitual physical activity levels. Tobacco use (i.e. cigarettes and snus) at baseline was assessed from the question ‘Do you smoke or use snus on a daily basis?’. A binary variable was created where participants were categorised as current daily users of tobacco if they answered ‘Yes’ to the question. Those who answered ‘No’ were categorised as non-current users. Details for the measurement of self-reported habitual physical activity at baseline is presented elsewhere.19 Briefly, habitual physical activity was calculated by taking the average of self-reported physical activity in winter and summer, including the estimated frequency and intensity of physical activity.

Statistical analysis

Characteristics and outcomes of the participants across physical exercise groups were tested using the chi-square test for categorical variables and analysis of variance for the continuous data. Mean values are reported with standard deviations, if asymmetric then median with interquartile range are reported. We employed linear regression analysis, pooling all three exercise arms, to observe the effect of intensities of exercise on the $\dot{V}O_{2\text{max}}$ at follow-up in the crude and adjusted models. Models were adjusted for baseline $\dot{V}O_{2\text{max}}$, age, BMI and baseline depression severity. The association between post-treatment $\dot{V}O_{2\text{max}}$ and post-treatment depression severity were tested using linear regression models. The association was initially adjusted for pre-treatment $\dot{V}O_{2\text{max}}$ and pre-treatment MADRS score. The final model was further adjusted for exercise intensities, age and BMI. Analyses were repeated using the binary ‘treatment responder’ variable in logistic regression models. All tests performed were two tailed. Statistical significance was set at alpha $P < 0.05$. Multicollinearity was assessed by the VIF (variance inflation factor), all values were less than ten. Of the analytical sample 4.5% of data for post-treatment MADRS were missing thus the main analysis was limited to 105 participants. Statistical analysis was carried out in SPSS version 23.

Results

A total of 316 individuals participated in the study, of which 206 were excluded because of missing $\dot{V}O_{2\text{max}}$ data. Of the remaining
Rahman et al

110 participants, 33 were in the vigorous exercise group, 38 were in the moderate group and 39 were in the light exercise group (Supplementary Fig. 1).

Table 1 shows the characteristics of the study participants stratified by physical exercise group. Mean age ($P = 0.045$) and BMI ($P = 0.06$) was lower in the light exercise group compared with other exercise intensities. There was no statistical difference in gender, ethnicity, education, baseline antidepressant use, tobacco use or baseline self-reported physical activity.

Baseline depression severity did not differ between exercise groups and after 3 months of the intervention. Following the intervention, the mean depression scores were reduced for all three exercise groups in this sample. Moreover, an increased mean $\dot{V}O_{2}\text{max}$ was observed at follow-up for all three exercise groups. Pointwise changes in mean $\dot{V}O_{2}\text{max}$ were higher for the vigorous intensity group, followed by the moderate and light intensity group. However, no significant differences in mean $\dot{V}O_{2}\text{max}$ at baseline or follow-up were seen between the physical exercise arms. In the linear regression analysis, when adjusted for baseline characteristics and outcome of the participants divided by physical exercise group.

<table>
<thead>
<tr>
<th>Intensities of physical exercise (n = 110)</th>
<th>Vigorous (n = 33)</th>
<th>Moderate (n = 38)</th>
<th>Light (n = 39)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (s.d.)</td>
<td>44.42 (12.68)</td>
<td>43.29 (12.65)</td>
<td>38.08 (9.28)</td>
<td>0.045</td>
</tr>
<tr>
<td>Body mass index, mean (s.d.)</td>
<td>25.13 (3.56)</td>
<td>26.53 (4.38)</td>
<td>24.50 (3.51)</td>
<td>0.06</td>
</tr>
<tr>
<td>Gender, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>13 (39.4)</td>
<td>10 (26.3)</td>
<td>12 (30.8)</td>
<td>0.49</td>
</tr>
<tr>
<td>Women</td>
<td>20 (60.6)</td>
<td>28 (73.7)</td>
<td>27 (69.2)</td>
<td></td>
</tr>
<tr>
<td>Ethnicity, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Born in Sweden</td>
<td>26 (78.8)</td>
<td>27 (71.1)</td>
<td>34 (87.2)</td>
<td>0.22</td>
</tr>
<tr>
<td>Born outside of Sweden</td>
<td>7 (21.2)</td>
<td>11 (28.9)</td>
<td>5 (12.8)</td>
<td></td>
</tr>
<tr>
<td>Education, n (%)a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary</td>
<td>1 (3)</td>
<td>2 (5.4)</td>
<td>2 (5.1)</td>
<td>0.07</td>
</tr>
<tr>
<td>Secondary</td>
<td>9 (27.3)</td>
<td>19 (51.4)</td>
<td>9 (23.1)</td>
<td></td>
</tr>
<tr>
<td>Tertiary</td>
<td>23 (69.7)</td>
<td>16 (43.2)</td>
<td>28 (71.8)</td>
<td></td>
</tr>
<tr>
<td>Baseline antidepressants use, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>10 (30.3)</td>
<td>8 (21.1)</td>
<td>8 (20.5)</td>
<td>0.55</td>
</tr>
<tr>
<td>No</td>
<td>23 (69.7)</td>
<td>30 (78.9)</td>
<td>31 (79.5)</td>
<td></td>
</tr>
<tr>
<td>Baseline tobacco use, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current daily users</td>
<td>6 (18.2)</td>
<td>5 (13.2)</td>
<td>5 (12.8)</td>
<td>0.77</td>
</tr>
<tr>
<td>Non-current users</td>
<td>27 (81.8)</td>
<td>33 (86.8)</td>
<td>34 (87.2)</td>
<td></td>
</tr>
<tr>
<td>Baseline habitual</td>
<td>26.66 (27.25)</td>
<td>18 (22.83)</td>
<td>22 (27)</td>
<td>0.55</td>
</tr>
<tr>
<td>Physical activity, median (IQR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of physical exercise sessions, median (IQR)</td>
<td>14 (17)</td>
<td>13 (22)</td>
<td>15 (20)</td>
<td>0.92</td>
</tr>
<tr>
<td>$\dot{V}O_{2}\text{max}, \text{L/min (pre-treatment): mean (s.d.)}$</td>
<td>2.72 (0.56)</td>
<td>2.81 (0.67)</td>
<td>2.98 (0.63)</td>
<td>0.20</td>
</tr>
<tr>
<td>$\dot{V}O_{2}\text{max}, \text{L/min (post-treatment: mean (s.d.)}$</td>
<td>3.08 (0.72)</td>
<td>3.03 (0.75)</td>
<td>3.07 (0.69)</td>
<td>0.92</td>
</tr>
</tbody>
</table>

IQR, interquartile range. a. For the moderate intensity group n = 37 because of missing data for education.

Exploratory analysis found that baseline $\dot{V}O_{2}\text{max}$ did not predict depression at baseline or follow-up.

Table 2 shows the association between post-treatment $\dot{V}O_{2}\text{max}$ and post-treatment depression severity after 12 weeks of exercise (all exercise groups together). In the crude analysis, post-treatment $\dot{V}O_{2}\text{max}$ was not associated with depression. A negative association between post-treatment $\dot{V}O_{2}\text{max}$ and post-treatment depression severity (Model 1, $B = -3.52, 95\% \text{ CI} -6.08 \text{ to } -0.96$) was observed after adjusting for pre-treatment $\dot{V}O_{2}\text{max}$ values. Adjusting for exercise intensities, age and BMI made the association stronger (Model 2, $B = -3.89, 95\% \text{ CI} -6.53 \text{ to } -1.26$).

Logistic regression analyses exploring the proportion of treatment responders (at least 50% reduction in depression score) given the increase in post-treatment $\dot{V}O_{2}\text{max}$, yielded results comparable with those obtained with linear regression models (Table 3). An increased odds of treatment response were seen among individuals with higher post-treatment $\dot{V}O_{2}\text{max}$ (Model 1, odds ratio (OR) = 3.73, 95% CI 1.22–11.43; Model 2, OR = 4.53, 95% CI 1.35–15.17). Analyses also found that higher pre-treatment $\dot{V}O_{2}\text{max}$ was significantly associated with higher depression severity (Table 2) and low treatment response at follow-up (Table 3). Exploration of data reveal that treatment responders had lower $\dot{V}O_{2}\text{max}$ (mean 2.77, s.d. = 0.61) at baseline and had an 11.91% increase in $\dot{V}O_{2}\text{max}$ (mean 3.10, s.d. = 0.70) at follow-up whereas treatment non-responders had only a 2.67% increase in $\dot{V}O_{2}\text{max}$ at follow-up (Table 4).

Non-participation in the fitness test at baseline and follow-up did not differ proportionally between men and women, the intensity groups or in their depression severity both at baseline and follow-up. However, those who did not participate in the fitness test at baseline were more likely to be non-participants in the MADRS assessment at follow-up.

Discussion

Main findings and comparison with findings from other studies

The current study demonstrates that, regardless of exercise intensity and frequency, a post-exercise increase in $\dot{V}O_{2}\text{max}$ is an independent predictor of lower depression severity at follow-up. That is, a post-treatment increase in $\dot{V}O_{2}\text{max}$ was significantly associated with reductions in depression severity after adjustment for relevant covariates. Moreover, increased $\dot{V}O_{2}\text{max}$ was found to be associated with higher odds of treatment response at follow-up. Also, participants with higher baseline $\dot{V}O_{2}\text{max}$ had a smaller increase in $\dot{V}O_{2}\text{max}$ and were less likely to have responded to treatment (50% score reduction).

The seminal work of Martinsen et al demonstrated that exercise training resulted in lower depression, and increased oxygen uptake compared with a control condition. Consistent with this, our study showed that 12 weeks of exercise was associated with reduced depression severity, which was independently related to increased physical fitness. Previous studies have primarily focused on assessing the effect of exercise among people with depression rather than if changes in fitness per se predict depression recovery. A recent single-blind randomised controlled trial (n = 57 patients aged 18–55 years) with major depressive disorder found that $\dot{V}O_{2}\text{max}$ significantly increased in the add-on aerobic exercise group at follow-up whereas no change was seen in the control group. However, in this study $\dot{V}O_{2}\text{max}$ was not found to be a significant predictor of treatment response. Similarly, Kerling et al reported that maximum oxygen consumption did not differ significantly between exercise (includes patients with depression) and control (includes healthy participants) groups, although exercise (within-group) resulted in significant improvements in

https://doi.org/10.1192/bjp.2018.45 Published online by Cambridge University Press
Cardiorespiratory fitness and response to exercise treatment in depression

Table 2  Linear regression models of the association between post-treatment VO2max (L/min) and post-treatment depression severity

<table>
<thead>
<tr>
<th></th>
<th>Crude model</th>
<th>Model 1(^a) (n = 105)</th>
<th>Model 2(^a) (n = 105)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>B (95% CI) P</td>
<td>B (95% CI) P</td>
</tr>
<tr>
<td>VO2max, L/min (post treatment)</td>
<td>-0.92 (-2.70 to 0.86) 0.31</td>
<td>-3.52 (-6.08 to -0.96) 0.007</td>
<td>-3.89 (-6.53 to -1.26) 0.004</td>
</tr>
<tr>
<td>VO2max, L/min (pre-treatment)</td>
<td>0.48 (-1.48 to 2.45) 0.63</td>
<td>3.88 (1.06 to 6.70) 0.007</td>
<td>3.76 (0.79 to 6.73) 0.013</td>
</tr>
<tr>
<td>MADRS (pre-treatment)</td>
<td>0.40 (0.22 to 0.57) &lt;0.001</td>
<td>0.41 (0.24 to 0.58) &lt;0.001</td>
<td>0.41 (0.25 to 0.58) &lt;0.001</td>
</tr>
</tbody>
</table>

MADRS, Montgomery-Åsberg Depression Rating Scale.
\(a\) Model 1 adjusted for pre-treatment VO2max and pre-treatment MADRS score; model 2 adjusted for model 1 + exercise intensities, age and body mass index.

To our knowledge this is the first study to report such associations. The observed associations in the current study suggest the presence of biological pathways between VO2max and depression severity. An experimental study has shown that erythropoietin elevates VO2max in mice when injected artificially;\(^{23}\) studies in humans have shown the same response.\(^{24,25}\)

Previous studies indicate improvements in cognitive abilities in individuals with depression following erythropoietin administration.\(^{26}\) These studies indicate a direct effect from increased VO2max (even when increased artificially), rather than an effect from the physical activity.

In addition, psychological factors might also explain the observed association but it is less likely that psychological factors alone could have played a major role in the present study as we used submaximal exercise tests, which are less demanding. Another possible contributor to the relationship between lower depression symptom severity and higher CRF or VO2max could be that individuals whose depression severity are reduced experience less fatigue during stress testing than before because the somatic symptoms often associated with depression, such as muscle soreness, weakness and low back pain have been reduced/are less prevalent.\(^{27}\)

There is currently no consensus as to which intensity, duration and frequency of exercise are optimal for treating individuals who are depressed.\(^{27}\) However, a recent meta-analysis provides indications of favourable antidepressants treatment effects from moderate and vigorous intensities.\(^{28}\) Given the stronger effect of vigorous exercise on VO2 levels, it may be reasonable to recommend higher intensity exercise to those with depression. However, the advantages of vigorous exercise should be balanced with the higher physical and mental demands and higher risk for injuries and drop-out /non-adherence,\(^{29}\) especially if the exercises are not supervised by trained healthcare professionals. In contrast, some reviews recommended moderate aerobic exercise, three to four times per week for at least 10–16 weeks.\(^{30}\) The present study adjusted for exercise intensity to control for the treatment bias. Given the small number of participants in each exercise arm, it was impractical to present findings stratified by exercise group.

Therefore, no recommendation regarding the optimal choice of exercise intensity could be derived from these findings.

Implications

Given the link between VO2max, depression, and cardiovascular disease (CVD),\(^{6,31,32}\) it is likely that prevention of depression and CVDs among people at risk of these diseases could be accelerated by improving VO2max. In clinical populations, special attention should be given to individuals with comorbid depression and CVD, which is a relatively common phenomenon.\(^{33}\) Further, any use of physical exercise on prescription should arguably take into account the ability of the prescribed activity regimen to improve VO2max. The participants included in the present study had similar fitness levels (average VO2max at baseline approximately 2.84 L/min) as found in a study of the general population.\(^{34}\) It is possible that the treatment potential is larger in less fit individuals and that a ceiling effect is present. However, since the average fitness level in our study was close to the lowest optimal fitness levels, any increase in fitness may have important effects on CVD risk reduction.

Strengths and limitations

Strengths of the present study include the relatively large sample size, clinician-rated depression and investigation of relevant covariates that could affect the observed association. In addition, our design provided good internal validity. Limitations include limited test–retest reliability for VO2max in the general population; the error could be as high as 7%;\(^{35}\) thus, these findings require further replication with larger sample sizes. Additionally, familiarisation with the test was not possible in this study. Our study sample did not include patients with severe depression, therefore, caution should be taken generalising our findings to the entire population with depression, or to the general public. However, as most individuals with mild-to-moderate depression do not seek healthcare, and given the high prevalence of this disease, there is substantial treatment potential from increased exercise and/or aerobic capacity. Additionally, higher drop-out rates among the non-participants of the fitness test could have introduced selection bias in the study and underestimated the observed association. Despite the fact this is the largest study to date, more research in a larger sample is needed to confirm or refute the current findings.

In conclusion, our findings suggest that improvement in VO2max is an important and independent predictor of treatment

Table 3  The association between post-treatment VO2max (L/min) and treatment response to depression

<table>
<thead>
<tr>
<th></th>
<th>Crude model</th>
<th>Model 1(^a) (n = 105)</th>
<th>Model 2(^a) (n = 105)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR (95% CI) P</td>
<td>OR (95% CI) P</td>
<td>OR (95% CI) P</td>
</tr>
<tr>
<td>VO2max, L/min (post treatment)</td>
<td>1.04 (0.59–1.82) 0.87</td>
<td>3.73 (1.22–11.43) 0.02</td>
<td>4.53 (1.35–15.17) 0.014</td>
</tr>
<tr>
<td>VO2max, L/min (pre-treatment)</td>
<td>0.58 (0.31–1.08) 0.09</td>
<td>0.18 (0.06–0.61) 0.005</td>
<td>0.17 (0.05–0.60) 0.006</td>
</tr>
<tr>
<td>MADRS (pre-treatment)</td>
<td>1.03 (0.97–1.09) 0.27</td>
<td>1.03 (0.96–1.09) 0.35</td>
<td>1.02 (0.96–1.09) 0.37</td>
</tr>
</tbody>
</table>

MADRS, Montgomery-Åsberg Depression Rating Scale.
\(a\) Model 1 adjusted for pre-treatment VO2max and pre-treatment MADRS score; model 2 adjusted for model 1 + exercise intensities, age and body mass index.

Published online by Cambridge University Press
response in adults with mild-to-moderate depression. This finding indicates the presence of potential biological pathways that warrant further exploration.

Funding

The Regassa study was funded by the Vårdal Foundation, six county councils (Stockholm, Västra Götaland, Skåne, Blekinge, Kronoberg and Västmanland). O.E. was funded by ICA Sverige. The funders were not involved at any stage in the design, data collection, data analysis, interpretation of the results or decision to publish the present work.

Md Shafiquir Rahman, Research Assistant, Department of Public Health Sciences, Karolinska Institutet, Sweden; Björn Helgadóttir, Post-Doctoral Researcher, Department of Public Health Sciences, Karolinska Institutet and Division of Insurance Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Sweden; Mats Hallgren, Assistant Professor, Department of Public Health Sciences, Karolinska Institutet, Sweden; Yvonne Forsell, Professor, Department of Public Health Sciences, Karolinska Institutet and Centre for Epidemiology and Community Medicine, Stockholm County Council, Sweden; Brendon Stubbs, Research Physiologist, Physiotherapy Department, South London and Maudsley NHS Foundation Trust and Health Service and Population Research Department, King’s College London and Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, UK; Davy Vancampfort, Post-Doctoral Research Fellow, Department of Rehabilitation Sciences and University Psychiatric Center, KU Leuven, Belgium; Örjan Ekblom, Associate Professor, Department of Sport and Health Sciences, Åstrand Laboratory of Work Physiology, The Swedish School of Sport and Health Sciences, Sweden.

Correspondence: Örjan Ekblom, Swedish School of Sport and Health Sciences, GH, Department of Sport and Health Sciences, Åstrand Laboratory of Work Physiology, Box 5626, Lidingövagen 1, 114 86 Stockholm, Sweden. Email: orjan.ekblom@kth.se

First received 30 Nov 2017, final revision 9 Jun 2018, accepted 02 Jul 2018

Acknowledgement

We gratefully acknowledge the advice provided to the statistical analysis by Zanjin Zeebri, PhD.

Supplementary material

Supplementary material is available online at https://doi.org/10.1192/bjo.2018.45.

References


Table 4 Number of treatment responders and non-responders and their corresponding VO2max (L/min) profile at baseline and follow-up (n = 105)

<table>
<thead>
<tr>
<th>Treatment responder</th>
<th>Treatment non-responder</th>
</tr>
</thead>
<tbody>
<tr>
<td>n (%)</td>
<td>63 (60)</td>
</tr>
<tr>
<td>VO2max, L/min (pre-treatment), mean (s.d.)</td>
<td>2.77 (0.61)</td>
</tr>
<tr>
<td>VO2max, L/min (post-treatment), mean (s.d.)</td>
<td>3.10 (0.70)</td>
</tr>
<tr>
<td>% of VO2max increased at post-treatment</td>
<td>11.91 2.67</td>
</tr>
</tbody>
</table>

https://doi.org/10.1192/bjo.2018.45 Published online by Cambridge University Press


